Login
Navigate Fool.com
Will RGEN beat
the market?

Repligen Corp

NASDAQ: RGEN

Community Rating: 4 Stars: Favorite

15.84 0.44 (2.86%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $15.30
Previous Close $15.40
Daily Range $15.22 - $16.22
52-Week Range $7.37 - $17.26
Market Cap $505.9M
P/E Ratio 31.68
Dividend (Yield) $0.00 (0.0%)
Volume 5,367,267
Average Daily Volume 778,713
Current FY EPS $0.25

How do you think RGEN
will perform against the market?

Top RGEN Bull/Bear Pitches

 

zzlangerhans (< 20)
Submitted December 18, 2009

Repligen gets a green thumb for flirting with the one year low on lousy results of their phase III trial of secretin as an adjunct for pancreatic MRI. Disappointing I guess, but I don't know about a 2 … More

2 Replies Reply Report this Post
 

zzlangerhans (< 20)
Submitted April 17, 2008

Repligen has risen twice in the last six months on settlements of patent disputes. Aside from that, the company appears to have little going for it. The pipeline seems dubious to me. Pancreatic duct e … More

0 Replies Reply Report this Post

News & Commentary

3 Humongous Health-Care Stocks This Week

It was a shortened trading week, but these health-care stocks still racked up huge gains.

Mid-Morning Market Update: Markets Gain; Johnson & Johnson Profit Beats Street View

Why Repligen Corporation Shares Were Slammed

Repligen shares sink after the company reports its fourth-quarter earnings results. Is this dip a buying opportunity or a reason to keep your distance.

This Week in Biotech: Clinical Success, Plus Wheeling and Dealing

Two positive clinical results, a symbiotic asset deal, and a rumored takeover target are this week's top stories in Part 2 of "This Week in Biotech."

Why Repligen Corporation Shares Jumped

Repligen announces a deal to unload a non-core asset and shareholders cheer the decision.

Repligen, Continuing Overhaul, Flips Rare Disease Drugs to BioMarin

How Will the Bottom Line Change for Repligen in 2014?

Repligen will lose an important royalty revenue stream from Bristol-Myers Squibb this year. How will that affect the bottom line for investors?

How Will the Top Line Change for Repligen in 2014?

Repligen will lose an important royalty revenue stream from Bristol-Myers Squibb this year. How will that affect its top line for investors?

3 Health Care Investments Immune From FDA Scrutiny

Veeva Systems, Express Scripts, and Repligen operate in the health care space but don't rely on the good graces of FDA regulators.

What Should Investors Expect From Repligen in 2014?

Shares of Repligen doubled in 2013. While you shouldn't expect that kind of growth every year, there is plenty to look forward to in 2014.

See More RGEN News...

Sector

Healthcare

Industry

Drugs

Repligen Corp (RGEN) Description

A biopharmaceutical company focused on the development of novel therapeutics for the treatment of diseases of the central nervous system. Website: http://www.repligen.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks